A prospective study:the clinical value of acidosis correction by acetate free biofiltration (AFB) in hemodialysis patients.

A prospective study:the clinical value of acidosis correction by acetate free biofiltration (AFB) in hemodialysis patients. - A prospective study:the clinical value of acidosis correction by acetate free biofiltration (AFB) in hemodialysis patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000519

Enrollment

Registered

2006-11-30

Start date

2006-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysdialysis syndrome

Interventions

1)Hemodiafiltration(HDF) 2)AFB(bicarbonate high control) 3)AFB(bicarbonate low control)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)written informed consent and dysdialysis syndrom. (2)receive hemodialysis 3 times a week and a hemodialysis of 4 hours at a time.

Exclusion criteria

Exclusion criteria: (1)chronic inflammation, malignant disorder, severe respiratory organs and liver disorder, heart failure (2)20 years or older. (3)participating in another clinical trial for 12 weeks or longer. (4)pregnant, during the nursing, possibly pregnant and having the hope of child bearing. (5)judged inappropriate as study subject by the investigator.

Design outcomes

Primary

Measure	Time frame
Efficacy (1)stabilization of circulation dynamics (2)improvement of QOL (3)correction of acidosis (4)rHuEPO dosage	—

Countries

Japan

Contacts

Public ContactHirokazu Honda

Showa University of Medicine Department of Nephrology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026